Lyra Therapeutics (LYRA) Change in Account Payables (2019 - 2025)
Lyra Therapeutics (LYRA) recorded quarterly Change in Account Payables of $103000.0 in Q4 2025, up 185.83% on a QoQ basis from -$120000.0 in Q3 2025, and up 109.25% YoY from $49222.4 in Q4 2024.
Lyra Therapeutics (LYRA) Change in Account Payables (2019 - 2025) Analysis & Trends
Lyra Therapeutics (LYRA) has reported Change in Account Payables for 7 consecutive years, with $103000.0 the latest figure, recorded in Q4 2025.
- Change in Account Payables for Q4 2025 came in at $103000.0, up 109.25% year-over-year; the trailing twelve-month figure through Dec 2025 was -$516000.0 (up 72.66% YoY), and the FY2025 annual result was -$516000.0, up 72.66% from the prior year.
- Change in Account Payables for Q4 2025 stood at $103000.0, up from -$120000.0 in the prior quarter.
- The five-year high for Change in Account Payables was $3.3 million in Q1 2023, with the low at -$3.5 million in Q4 2023.
- A 5-year average of -$100700.0 and a median of -$75500.0 in 2023 frame the typical range for Change in Account Payables.
- Across the five-year window, Change in Account Payables surged 14033.33% in 2021 and slumped 435.4% in 2022, its largest moves.
- Lyra Therapeutics' Change in Account Payables stood at $1.2 million in 2021, then plunged by 289.69% to -$2.2 million in 2022, then sank by 57.53% to -$3.5 million in 2023, then jumped by 68.51% to -$1.1 million in 2024, then surged by 109.25% to $103000.0 in 2025.
- The last three Change in Account Payables figures came in at $103000.0 (Q4 2025), -$120000.0 (Q3 2025), and -$45000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Lyra Therapeutics | 70,995.28 | 70,995.28 | - | 103,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 103,000.00 |
| Dec 31, 2025 | 103,000.00 |
| Sep 30, 2025 | -120,000.00 |
| Sep 30, 2025 | -120,000.00 |
| Jun 30, 2025 | -45,000.00 |
| Jun 30, 2025 | -45,000.00 |
| Mar 31, 2025 | -454,000.00 |
| Mar 31, 2025 | -454,000.00 |
| Dec 31, 2024 | -1.11 Mn |
| Dec 31, 2024 | -1.11 Mn |
| Sep 30, 2024 | -2.59 Mn |
| Sep 30, 2024 | -2.59 Mn |
| Jun 30, 2024 | 2.38 Mn |
| Jun 30, 2024 | 2.38 Mn |
| Mar 31, 2024 | -560,000.00 |
| Mar 31, 2024 | -560,000.00 |
| Dec 31, 2023 | -3.54 Mn |
| Dec 31, 2023 | -3.54 Mn |
| Sep 30, 2023 | 796,000.00 |
| Sep 30, 2023 | 796,000.00 |